Business
PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc.&#x...
About this update from Preveceutical Medical Inc
[{"type":"text","content":"PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer UpdateVancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the \"Company\" or \"PreveCeutical\"), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the International patent application forward in the US, Europe, Canada and Australia.The US patent application (USSN 18/003,768) has been filed with amended claims, together with its Australian and Canadian counterparts, and the European application is being filed before the 31-month deadline of 1 February 2023. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as we continue our clinical process.PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, \"We are ensuring that the peptides identified for possible therapies in our research projects, including possible therapies for cancer and non-addictive analgesic for pain management, are well protected. We are continuing to work with government agencies, potential partners, and investors to assist in developing these anticipated therapies.\"The Company also announces that Ms. Rajan has resigned, effective January 15, 2023, as the Chief Financial Officer. Ms. Rajan will remain a consultant in assisting the CEO and financial department moving forward. Mr. Stephen Van Deventer has been appointed the interim Chief Financial Officer. The Company has retained the services of Treewalk Consulting Inc. to provide financial reporting and support services.Mr. Van Deventer further commented, \"We thank Ms. Rajan for serving as the Company's CFO for the past six years and are delighted that she will continue assisting the company in a smaller capacity.\"Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.About P...